Final Remarks and Thank-You

Video content above is prompted by the following:

1. Thus far, how do the objective clinical outcomes from emerging, targeted therapies for ES-SCLC compare with second-line topotecan and CAV regimens in subsequent lines of treatment?
   1. With respect to platinum-sensitive vs platinum-resistant disease, which compounds in development exhibit the most potential as later lines of therapy in these 2 ES-SCLC subgroups?
2. Do you envision clinical applicability of IO therapy with a T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor for SCLC?
   1. Prior to its adoption as a therapeutic option, what clinical trials data must confirm its safety and efficacy as
      1. Monotherapy
      2. Combination therapy
      3. Importantly, in what treatment line?
         
   2. Given the objective response and progression-free survival rates reported in the Phase 2 CITYSCAPE trials, does tiragolumab co-administered with a PD-L1 inhibitor suggest its more likely role in the treatment of chemotherapy-naive, PD-L1-positive, recurrent, or metastatic non–small cell lung cancer than in ES-SCLC?